NovoGro Injectable
Bone defects (minimally invasive applications)
Pre-clinicalActive
Key Facts
Indication
Bone defects (minimally invasive applications)
Phase
Pre-clinical
Status
Active
Company
About Osteonovus
OsteoNovus is a commercial-stage orthopedic company with an FDA-cleared product, NovoGro Putty, for bone regeneration. Its core innovation is a bioactive synthetic graft material that mimics natural bone mineral, encouraging rapid bone ingrowth and remodeling, as evidenced by robust preclinical data showing new bone formation within six weeks. The company is advancing its pipeline with an injectable formulation of NovoGro, aiming to expand its addressable market into minimally invasive procedures. Operating from the orthopedic hub of Memphis, OsteoNovus is positioned to capture share in the large and growing bone graft substitute market.
View full company profile